Literature DB >> 21832144

Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder.

Eszter Székely1, Péter Törzsök, Péter Riesz, Anna Korompay, Attila Fintha, Tamás Székely, Gábor Lotz, Péter Nyirády, Imre Romics, József Tímár, Zsuzsa Schaff, András Kiss.   

Abstract

The members of the claudin family are major integral transmembrane protein constituents of tight junctions. Normal and neoplastic tissues can be characterized by unique qualitative and quantitative distribution of claudin subtypes, which may be related to clinicopathological features. Differential diagnosis and prognosis of nonmuscle invasive tumor entities of urinary bladder epithelium are often challenging. The aim was to investigate the expression profile of claudins in inverted urothelial papillomas (IUPs), urothelial papillomas (UPs), papillary urothelial neoplasms of low malignant potential (PUNLMPs), and intraepithelial (Ta), low-grade urothelial cell carcinomas (LG-UCCs) in order to reveal potential prognostic and differential diagnostic values of certain claudins. Claudin-1, -2, -4, and -7 protein expressions detected by immunohistochemistry and clinical data were analyzed in 15 IUPs, 20 UPs, 20 PUNLMPs, and 20 LG-UCCs. UPs, PUNLMPs, and LG-UCCs showed significantly decreased claudin-1 expression in comparison to IUPs. LG-UCCs expressing claudin-4 over the median were associated with significantly shorter recurrence-free survival. PUNLMPs expressing claudin-1 over the median revealed significantly longer recurrence-free survival. High claudin-1 protein expression might help to differentiate IUP from UPs, PUNLMPs, and LG-UCCs. High claudin-4 expression may determine an unfavorable clinical course of LG-UCCs, while high claudin-1 expression in PUNLMP was associated with markedly better clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21832144      PMCID: PMC3201131          DOI: 10.1369/0022155411418829

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  35 in total

Review 1.  Morphological diagnosis of urothelial neoplasms.

Authors:  R Montironi; R Mazzucchelli; M Scarpelli; A Lopez-Beltran; L Cheng
Journal:  J Clin Pathol       Date:  2007-06-01       Impact factor: 3.411

2.  Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin.

Authors:  S T Mees; R Mennigen; T Spieker; E Rijcken; N Senninger; J Haier; M Bruewer
Journal:  Int J Colorectal Dis       Date:  2009-01-29       Impact factor: 2.571

3.  FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

Authors:  Johanna M M van Oers; Peter J Wild; Maximilian Burger; Stefan Denzinger; Robert Stoehr; Elke Rosskopf; Ferdinand Hofstaedter; Ewout W Steyerberg; Monika Klinkhammer-Schalke; Ellen C Zwarthoff; Theodorus H van der Kwast; Arndt Hartmann
Journal:  Eur Urol       Date:  2007-01-12       Impact factor: 20.096

4.  Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.

Authors:  Gregory M Sheehan; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Jeffrey S Ross
Journal:  Hum Pathol       Date:  2007-02-15       Impact factor: 3.466

5.  Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer.

Authors:  Tetsushi Kinugasa; Qun Huo; Daijiro Higashi; Hirotomo Shibaguchi; Motomu Kuroki; Toshihiro Tanaka; Kitarou Futami; Yuichi Yamashita; Ken Hachimine; Shinichi Maekawa; Kazuki Nabeshima; Hiroshi Iwasaki; Masahide Kuroki
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

6.  Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.

Authors:  Serge Paschoud; Massimo Bongiovanni; Jean-Claude Pache; Sandra Citi
Journal:  Mod Pathol       Date:  2007-06-22       Impact factor: 7.842

7.  Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.

Authors:  Maryla Krajewska; Allen H Olson; Dan Mercola; John C Reed; Stan Krajewski
Journal:  Prostate       Date:  2007-06-15       Impact factor: 4.104

8.  Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.

Authors:  Timothy D Jones; Shaobo Zhang; Antonio Lopez-Beltran; John N Eble; Ming-Tse Sung; Gregory T MacLennan; Rodolfo Montironi; Puay-Hoon Tan; Suqin Zheng; Lee Ann Baldridge; Liang Cheng
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394

9.  Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract.

Authors:  Kuniaki Nakanishi; Sho Ogata; Sadayuki Hiroi; Susumu Tominaga; Shinsuke Aida; Toshiaki Kawai
Journal:  Am J Clin Pathol       Date:  2008-07       Impact factor: 2.493

Review 10.  Tight junctions and the modulation of barrier function in disease.

Authors:  Carola Förster
Journal:  Histochem Cell Biol       Date:  2008-04-16       Impact factor: 4.304

View more
  12 in total

Review 1.  The Urothelium: Life in a Liquid Environment.

Authors:  Marianela G Dalghi; Nicolas Montalbetti; Marcelo D Carattino; Gerard Apodaca
Journal:  Physiol Rev       Date:  2020-03-19       Impact factor: 37.312

2.  Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder.

Authors:  Péter Törzsök; Péter Riesz; István Kenessey; Eszter Székely; Aron Somorácz; Péter Nyirády; Imre Romics; Zsuzsa Schaff; Gábor Lotz; András Kiss
Journal:  J Histochem Cytochem       Date:  2011-11       Impact factor: 2.479

3.  The prognostic role of claudins in head and neck squamous cell carcinomas.

Authors:  Györgyi A Nelhűbel; Boróka Károly; Balázs Szabó; Gábor Lotz; András Kiss; József Tóvári; István Kenessey
Journal:  Pathol Oncol Res       Date:  2013-07-12       Impact factor: 3.201

Review 4.  The urothelium: a multi-faceted barrier against a harsh environment.

Authors:  Nazila V Jafari; Jennifer L Rohn
Journal:  Mucosal Immunol       Date:  2022-09-30       Impact factor: 8.701

5.  Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas.

Authors:  Ágnes Holczbauer; Benedek Gyöngyösi; Gábor Lotz; Attila Szijártó; Péter Kupcsulik; Zsuzsa Schaff; András Kiss
Journal:  J Histochem Cytochem       Date:  2013-02-05       Impact factor: 2.479

6.  Low expression of claudin-4: an indicator of recurrence in esophageal squamous cell carcinoma after Ivor Lewis esophagectomy?

Authors:  Mo Shi; Zhou Wang; Liang Song; Dong Wang; Zhi Sun
Journal:  Med Oncol       Date:  2014-04-16       Impact factor: 3.064

7.  Overexpression of Claudin-1 is Associated with Advanced Clinical Stage and Invasive Pathologic Characteristics of Oral Squamous Cell Carcinoma.

Authors:  Kraisorn Sappayatosok; Ekarat Phattarataratip
Journal:  Head Neck Pathol       Date:  2014-07-31

8.  Cell-surface markers for colon adenoma and adenocarcinoma.

Authors:  Kamini Sewda; Domenico Coppola; Steven Enkemann; Binglin Yue; Jongphil Kim; Alexis S Lopez; Jonathan W Wojtkowiak; Valerie E Stark; Brian Morse; David Shibata; Shivakumar Vignesh; David L Morse
Journal:  Oncotarget       Date:  2016-04-05

9.  High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.

Authors:  Sohaib Abu-Farsakh; Tongtong Wu; Amy Lalonde; Jun Sun; Zhongren Zhou
Journal:  BMC Gastroenterol       Date:  2017-02-17       Impact factor: 3.067

10.  Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.

Authors:  Minsun Jung; Jeong Hoon Lee; Bohyun Kim; Jeong Hwan Park; Kyung Chul Moon
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.